Dublin, March 13, 2026 (GLOBE NEWSWIRE)-- The "Roferon-a Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Roferon-A is an injectible, ...
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Roferon-A is an injectible, ...
Dec. 22, 2004 — The U.S. Food and Drug Administration (FDA) approved in October revisions to drug safety labeling to advise healthcare professionals of the following changes: use of the multidose ...
To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) with recombinant human interferon alfa-2a (Roferon-A; Hoffman La-Roche AG, Basel, Switzerland) versus the ...
Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. A total of 496 previously untreated colorectal cancer patients were randomized to receive either Roferon-A (9 MIU) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results